These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33851571)

  • 21. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
    Jain M; Badwal S; Pandey R; Srivastava A; Sharma RK; Gupta RK
    Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methods and objectives of a large US multicenter case-control study of post-transplant lymphoproliferative disorder in renal transplant patients.
    Funch DP; Brady J; Ko HH; Dreyer NA; Walker AM
    Recent Results Cancer Res; 2002; 159():81-8. PubMed ID: 11785847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
    Colombini E; Guzzo I; Morolli F; Longo G; Russo C; Lombardi A; Merli P; Barzon L; Murer L; Piga S; Ciofi Degli Atti ML; Locatelli F; Dello Strologo L
    Pediatr Nephrol; 2017 Aug; 32(8):1433-1442. PubMed ID: 28280938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Small intestinal involvement by lymphoproliferative disorders post-renal transplantation: a report from the post-transplant lymphoproliferative disorder international survey.
    Khedmat H; Taheri S
    Saudi J Kidney Dis Transpl; 2013 May; 24(3):487-94. PubMed ID: 23640619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymphoma after living donor kidney transplantation: an Iranian multicenter experience.
    Pourfarziani V; Taheri S; Lessan-Pezeshki M; Nourbala MH; Simforoosh N; Nemati E; Makhdoomi K; Ghafari A; Ahmadpour P; Nafar M; Einollahi B
    Int Urol Nephrol; 2008; 40(4):1089-94. PubMed ID: 18592392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of a Post-Transplant Lymphoproliferative Disorder Risk Prediction Score and Derivation of a New Prediction Score Using a National Bone Marrow Transplant Registry Database.
    Lee CC; Hsu TC; Kuo CC; Liu MA; Abdelfattah AM; Chang CN; Yao M; Li CC; Wu KH; Chen TC; Gau JP; Wang PN; Liu YC; Chiou LW; Lee MY; Li SS; Chao TY; Jou ST; Chang HH
    Oncologist; 2021 Nov; 26(11):e2034-e2041. PubMed ID: 34506688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Posttransplant lymphoproliferative disorder in pediatric renal transplantation.
    Srivastava T; Zwick DL; Rothberg PG; Warady BA
    Pediatr Nephrol; 1999 Nov; 13(9):748-54. PubMed ID: 10603113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
    Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
    Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
    Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Posttransplant Lymphoproliferative Disorder in Kidney and Liver Transplant Recipients: A Single-Center Experience.
    Wójciak M; Gozdowska J; Dęborska-Materkowska D; Perkowska-Ptasińska A; Kosieradzki M; Nazarewski S; Durlik M
    Transplant Proc; 2018 Sep; 50(7):2154-2158. PubMed ID: 30177129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved survival with recent Post-Transplant Lymphoproliferative Disorder (PTLD) in children with kidney transplants.
    Dharnidharka VR; Martz KL; Stablein DM; Benfield MR
    Am J Transplant; 2011 Apr; 11(4):751-8. PubMed ID: 21446977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis.
    Stein EM; Bonifacio G; Latrémouille-Viau D; Shi S; Guérin A; Wu EQ; Sadek I; Cao X
    J Med Econ; 2021; 24(1):234-243. PubMed ID: 33472483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center.
    Cockfield SM; Preiksaitis JK; Jewell LD; Parfrey NA
    Transplantation; 1993 Jul; 56(1):88-96. PubMed ID: 8333073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinicopathologic study of post-transplant lymphoproliferative disorders].
    Zhang YN; Zhou XG; Wang CZ; Wei P; Zhang SH; Zheng YY
    Zhonghua Bing Li Xue Za Zhi; 2006 Apr; 35(4):209-12. PubMed ID: 16776977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence, Risk Factors, Clinical Management, and Outcomes of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients.
    Liu M; Husain S; Famure O; Li Y; Kim SJ
    Prog Transplant; 2019 Jun; 29(2):185-193. PubMed ID: 30845885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cost implications of first anniversary renal function after living, standard criteria deceased and expanded criteria deceased donor kidney transplantation.
    Schnitzler MA; Gheorghian A; Axelrod D; L'Italien G; Lentine KL
    J Med Econ; 2013; 16(1):75-84. PubMed ID: 22905738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-transplantation lymphoproliferative disorder in pediatric kidney-transplant recipients - a national study.
    Cleper R; Ben Shalom E; Landau D; Weissman I; Krause I; Konen O; Rahamimov R; Mor E; Bar-Nathan N; Frishberg Y; Davidovits M
    Pediatr Transplant; 2012 Sep; 16(6):619-26. PubMed ID: 22708682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-transplant lymphoproliferative disorders in lung transplant recipients: 20-yr experience at the University of Minnesota.
    Wudhikarn K; Holman CJ; Linan M; Blaes AH; Dunitz JM; Hertz ME; Peterson BA
    Clin Transplant; 2011; 25(5):705-13. PubMed ID: 21077949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler.
    Leung E; Shenton BK; Green K; Jackson G; Gould FK; Yap C; Talbot D
    Transpl Infect Dis; 2004 Dec; 6(4):156-64. PubMed ID: 15762933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.
    Taylor E; Jones M; Hourigan MJ; Johnson DW; Gill DS; Isbel N; Hawley CM; Marlton P; Gandhi MK; Campbell SB; Mollee P
    Nephrol Dial Transplant; 2015 Oct; 30(10):1774-9. PubMed ID: 26188340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.